January 1 to 31, 2026 · Executive brief
Thyroid Awareness Month 2026: Make Access and Follow-Through Visible
Use one month of awareness to test whether a person can move from a concern or abnormal result to an interpreted answer, a shared decision, and an accountable follow-through plan.
Awareness should reveal the route, not merely increase the volume.
The American Thyroid Association identifies January as 2026 Thyroid Awareness Month and presents the public message “Know Your Thyroid. Know Your Health.” The campaign invites people to learn the signs, seek appropriate evaluation, and take an active role in thyroid health. For healthcare leaders, that invitation creates an operating responsibility. If awareness prompts a question, a visit, a test, or a referral, the organization should be able to show what happens next.
That route is not one universal screening protocol. Thyroid-related concerns can arise through primary care, pregnancy care, nephrology, eye care, pharmacy, surgery, an emergency encounter, a laboratory result, or a person’s own questions. Symptoms may be nonspecific. Reference intervals can vary across laboratories. A result can require clinical context, repeat testing, or a different next step. Unnecessary imaging can generate cascades, while delayed or inaccessible evaluation can prolong uncertainty. The leadership task is therefore to make appropriate evaluation and reliable follow-through visible without converting an awareness campaign into individualized medical advice.
Can a person move from a concern or abnormal result to an interpreted answer, a shared decision, and an accountable follow-through plan without the pathway changing because of language, insurance, gender, laboratory, or entry point?
The evidence reviewed for this brief points to variation at several parts of that question. Patient voice may differ according to who makes the diagnosis and the specialty setting.1 Language status and insurance can be associated with the management routes people receive.37 Financial burden, weight stigma, and relationship quality can affect follow-through.618 Laboratory interpretation and test selection also need governance, because reference intervals, comorbid illness, and reflex algorithms change what a result means operationally.2414
What this brief does and does not do
This is an executive operating brief. It offers a method for examining access, diagnostic stewardship, communication, transitions, medication support, and measurement. It does not recommend population-wide thyroid screening, interpret a laboratory value, diagnose a condition, select a treatment, or alter medication. Those decisions belong to qualified clinicians using current guidance, individual history, examination, preferences, and applicable organizational policy.
Use the literature as a map of operating questions, not a ranking of solutions.
This brief draws on 18 peer-reviewed records published from 2022 through August 2026. The set includes reviews, meta-analyses, randomized trials, retrospective cohorts, registry and utilization studies, cross-sectional surveys, and a computational methods study. Each design answers a different question and carries different limits. The portfolio is organized below by the part of the operating system it most directly informs.
Accessible data and appropriate executive use
| Primary lens | Records | Appropriate use |
|---|---|---|
| Equity, voice, and access | 5 | Identify access and communication questions for local review. |
| Diagnostic and laboratory stewardship | 5 | Inform governance of test selection, interpretation, and reporting. |
| Treatment and follow-through | 3 | Frame medication-support and follow-up design questions. |
| Life-stage and cross-specialty coordination | 3 | Identify transitions that need explicit ownership. |
| Outcomes and shared decisions | 2 | Support preference-sensitive communication and cautious outcome claims. |
Limitation: Counts show how this review assigned each record to one primary operating lens. They do not measure study quality, effect size, disease burden, priority, or strength of recommendation. Several records could reasonably fit more than one lens.
Diagnostic stewardship is contextual.
A narrative review of thyroid testing in kidney failure argues for repeat and contextual interpretation before levothyroxine treatment, while acknowledging that kidney-specific thresholds have not been prospectively validated.2 A computational harmonization study explored translation across laboratories with different reference intervals, but its small training dataset limits immediate generalization.4 A four-site retrospective study found a measurable subset of initial thyroid ultrasounds did not match its appropriateness criteria, and a regional utilization study reported substantial reductions in free-hormone testing after reinforcement of a reflex algorithm.1114
For leaders, these studies support governance questions rather than a single protocol: Are indications visible? Are exceptions safe? Does the laboratory report help the ordering clinician understand context? Can teams distinguish a clinically justified repeat from avoidable duplication? Do utilization changes preserve the ability to identify urgent or atypical presentations?
Access is more than appointment supply.
Recent observational work links patient voice, language status, insurance, financial burden, and weight stigma with parts of the thyroid-care experience.136718 These studies do not establish a universal causal pathway. They do, however, show why a dashboard limited to the next available appointment can miss whether a person understood the choice, could afford the route, experienced respect, completed the referral, or reached a definitive answer.
An access review should therefore connect schedule availability with language support, benefit and cost navigation, transportation and digital options, decision comprehension, referral acceptance, and closed-loop result communication. Stratification should be used to find locally meaningful differences, not to assign risk or intent to an individual.
Design one visible path from question to accountable closure.
A reliable route begins before a test is ordered and continues after a result appears. It should help a person understand why an evaluation is occurring, what result is expected next, who will interpret it, what choices may follow, and how the organization will know that the next step was accepted. The route also needs a safe branch for urgent concerns, uncertainty, discordant findings, pregnancy-related needs, eye symptoms, medication questions, and situations in which a specialty service is unavailable.
Limitation: This process is an executive workflow model, not a clinical algorithm. Local teams must define indications, urgency, intervals, decision rights, and exceptions using current professional guidance and organizational policy.
Start with a bounded pathway.
Do not attempt to redesign every thyroid-related encounter in one project. Select one entry point where ownership is currently ambiguous and where improvement can be observed within 90 days. A practical example is the route from an abnormal outpatient thyroid result to an interpreted plan that the person understands and the next owner accepts. Another could be the route from an indeterminate thyroid nodule result to decision support and documented follow-through. The latter requires special attention to insurance and access because a single-center study found lower odds of molecular testing among uninsured patients and a higher subsequent rate of thyroidectomy, while its observational design prevents a causal conclusion.7
Map the actual route, including workarounds. Identify where a result can sit without an owner, where a referral is considered “complete” before it is accepted, and where a person must call multiple offices to learn what happens next. Include laboratory professionals, primary care, endocrinology, nursing, pharmacy, referral operations, information technology, finance or benefit navigation, and people who have used the route. If pregnancy, thyroid eye disease, or surgical care is in scope, include the relevant specialty partners at the start rather than inviting them after the workflow is drafted.
Limitation: This fishbone is deliberately unranked. It is a hypothesis menu derived from the reviewed literature and operating practice. Local evidence and direct listening are required before any branch is treated as a cause.
Balance delayed response with avoidable cascade risk.
A reliable system cannot be designed around utilization reduction alone. Delayed evaluation can leave a person without an answer, while indiscriminate testing or imaging can expose that same person to repeat appointments, conflicting interpretations, procedures, cost, and uncertainty. The reviewed studies illuminate both sides of the tension. Kidney failure can complicate interpretation and create a need for contextual or repeated assessment.2 Cross-laboratory variation can complicate comparison.4 At the same time, inappropriate ultrasound and low-value free-hormone testing remain measurable stewardship concerns in the studied settings.1114
The executive control is not a blunt stop. It is a governed sequence with visible indications, safe exceptions, qualified interpretation, and balancing measures. If a reflex rule is introduced, teams should specify which presentations remain outside that rule, how an exception is requested, who reviews discordant or persistent findings, and how potential delay is monitored. If ultrasound ordering is reviewed, the organization should distinguish a study flag from an individual clinical conclusion and preserve a route for physical findings or other clinically justified indications. If repeat testing is reduced, the safety review should look for return visits, later escalation, complaints, and cases in which a result changed management.
Diagnostic stewardship also depends on communication. A person who receives “normal” without context may continue to seek an answer because the original concern remains unexplained. A clinician who receives a laboratory number without an accessible trend or relevant reference interval may repeat work to reconstruct the picture. A result message should therefore state who interpreted the information, what the conclusion means for the current question, whether another step is planned, and whom to contact if the concern changes. That is operational clarity, not a substitute for clinical judgment.
Define closure in language the person and the system can both verify.
Healthcare workflows often use words such as “notified,” “referred,” “scheduled,” and “followed” without defining what each one means. Those labels can hide incomplete work. A portal notification may show that a message was sent, but not that it was opened, understood, or accessible in the person’s preferred language. A referral may show as complete when the receiving service has not accepted it. A scheduled visit may be impossible because cost, transportation, work, caregiving, or digital access was never addressed. A follow-up order may exist without a named team responsible for acting on the next result.
For the pilot pathway, write observable closure states. “Interpreted result reached” might require a qualified interpretation, an approved communication channel, and a recorded next step. “Referral accepted” might require acknowledgment from the receiving service, instructions delivered to the person, and an owned contingency when the appointment cannot occur. “Medication issue closed” might require documentation of the identified problem, the response, and the responsible clinician’s disposition. The exact definitions should match local roles and policy, but they should not depend on unverified assumptions about patient preference or intent.
Direct listening is essential because administrative closure can still feel unresolved. Ask a small, representative sample of people to describe what they believe is happening, whom they would call, what cost or access barrier remains, and what would cause them to seek help sooner. Ask frontline staff where they use memory, personal relationships, duplicate messages, or manual tracking to keep the route moving. Treat those workarounds as information about the design. They may represent expertise worth formalizing, or risk that the organization should remove.
Finally, separate a learning measure from a performance judgment during the first 90 days. Teams are more likely to surface exceptions when the pilot makes it safe to report them. The early objective is to understand the route, test one change, and build a trustworthy definition. Accountability still matters, but premature ranking can encourage documentation that looks complete while leaving the underlying handoff unchanged.
Put the person’s question and goals at the center of shared ownership.
Thyroid care often crosses organizational boundaries that no single service controls. A laboratory can improve reporting but cannot ensure a referral is accepted. A specialist can offer options but may not see the financial burden or medication interactions that shape follow-through. A pharmacy can identify a drug-related problem but may lack a clear route to the prescriber. A person may receive technically accurate instructions from several teams that do not form one usable plan.
Limitation: The domains show shared responsibilities, not a required reporting structure. Roles and decision rights vary by organization, setting, scope of practice, and available services.
Voice and comprehension
Ask people to describe what they believe the result means, what choice they are making, and what happens next. A survey of women with thyroid conditions found differences in reported patient voice associated with the diagnosing clinician’s gender and specialty, but its cross-sectional self-report design cannot determine causality or fully separate forms of epistemic injustice.1 Use that finding to prompt listening and local observation, not to stereotype clinicians or patients.
Preference-sensitive choices
Language matters when people weigh surveillance and treatment. Research on low-risk papillary thyroid cancer found that disease labels and stated progression risk influenced treatment preferences in its study context.9 Leaders can support decision aids, balanced framing, interpretation services, and documentation of the person’s goals while leaving the clinical recommendation to the qualified care team.
Medication and monitoring support
A meta-analysis found no significant overall difference between morning and evening levothyroxine administration, while weekly regimens produced higher average TSH that remained within the reference range in the included trials.12 Small trials of teach-back with telephone follow-up and clinical pharmacist involvement reported improvements in selected adherence or drug-related-problem measures, with important limits in size, duration, setting, and registration.1316 The executive implication is to make reconciliation, instructions, interactions, access barriers, and monitoring responsibility explicit, not to prescribe a schedule through an awareness article.
Make cross-specialty transitions visible.
Some thyroid-care routes depend on coordinated specialty decisions. A current review of thyroid eye disease describes expanding medical options while noting cost, availability, adverse effects, and durability questions.5 Pregnancy introduces gestation-specific interpretation and ongoing controversy about case finding and management thresholds.15 A long-term retrospective study found higher subsequent hypothyroidism among people with thyroid abnormalities identified during pregnancy, but the single-system design and observational follow-up limit generalization.10 These findings support explicit handoffs among primary care, obstetric care, endocrinology, ophthalmology, surgery, pharmacy, and laboratory services when those domains are relevant.
Define what “accepted” means. A referral order is not the same as an appointment. An appointment is not the same as a completed consultation. A completed consultation is not the same as an understood plan. The sending team should know when responsibility transfers, the receiving team should acknowledge the transfer, and the person should know whom to contact during the interval. Exceptions should return to a visible queue with an owner and deadline.
Measure the reliability of the route, with equity and safety beside speed.
A strong dashboard begins with a written specification. Define the population, entry event, clock start, clock stop, exclusions, owner, review frequency, and balancing measure before comparing teams or demographic groups. A local operational measure is not a clinical guideline and should not be presented as one. A result-communication metric, for example, can measure whether a qualified interpretation reached the person without declaring which result required treatment.
| Signal | Local operational definition | Accountable owner | Denominator and boundary | Equity or safety check |
|---|---|---|---|---|
| Interpreted-result reach | Documented qualified interpretation communicated through an approved channel within the locally defined interval. | Ordering service | Eligible results entering the bounded pathway; exclude only predefined, auditable cases. | Compare reach and delay by language need, access channel, and site; review urgent exceptions separately. |
| Accepted next owner | Receiving service, clinician, or monitoring team acknowledges responsibility and the person receives the next-step instructions. | Referral operations plus receiving service | Cases for which the interpreted plan requires another owner. | Review insurance, cost, transportation, digital, and language barriers; never infer refusal from an unreturned call alone. |
| Decision comprehension | Documented use of an approved comprehension check for a preference-sensitive choice. | Decision-making clinician | Locally defined preference-sensitive encounters. | Audit interpreter availability, accessible formats, and whether the measure creates documentation burden without value. |
| Testing exception review | Out-of-sequence or repeated testing enters a qualified review sample with indication and outcome visible. | Laboratory-clinical governance group | Tests captured by the locally approved rule; do not treat the flag as proof of inappropriateness. | Check for delayed recognition, missed urgent presentations, and unequal access after any utilization change. |
| Medication-support closure | Identified access, interaction, instruction, or monitoring issue has a named response and documented disposition. | Pharmacy or designated care team | Medication issues identified within the pilot route. | Track unresolved cost barriers and avoid using refill history alone as a judgment about adherence. |
| Return-to-system exceptions | Unaccepted referrals, unreachable communications, conflicting instructions, and overdue actions return to an owned work queue. | Pathway operations lead | All exceptions generated by the bounded route. | Review repeat contacts, harm signals, complaints, and burden on patients and staff. |
Limitation: These are measurement specifications to adapt, not national benchmarks. A faster route is not necessarily a safer route. Pair timeliness with clinical review, patient experience, staff workload, and balancing measures.
Use stratification to ask better questions.
Recent studies suggest plausible differences associated with language, insurance, financial burden, gender, specialty setting, and stigma, but none can substitute for local measurement.136718 Stratify only when data quality, privacy, sample size, and governance permit. Combine quantitative patterns with protected listening. A difference may reflect access, referral patterns, clinical context, measurement error, population mix, or another mechanism. The purpose is to investigate and improve a route, not to label a person or workforce group.
Publish both what changed and what remains unknown. If a reflex testing rule reduces test volume, report the safety review and exception process beside the utilization change. If a navigation intervention shortens time to specialty care, show whether the visit was completed and whether the person understood the plan. If an education effort increases portal message volume, treat that as demand entering the system and ensure response capacity exists.
Run a bounded pilot from abnormal result to accepted plan.
The pilot below is designed for one outpatient pathway and one accountable executive sponsor. It assumes the organization will adapt clinical rules to current guidance and local policy. The work should include a patient or caregiver partner, frontline representatives, and the services that own testing, interpretation, communication, referral, medication support, and data. Use the first 30 days to define and observe, the next 30 to test a small change, and the final 30 to evaluate, decide, and publish a learning brief.
Accessible timeline details
| Workstream | Days 1–30 | Days 31–60 | Days 61–90 |
|---|---|---|---|
| Governance and scope | Charter | Review | Decision |
| Pathway mapping | Observe | Test route | Standardize |
| Diagnostic stewardship | Baseline | Pilot rule | Safety audit |
| Access and communication | Listen | Test support | Compare |
| Medication and follow-up | Define | Close issues | Assess |
| Measurement and exceptions | Specify | Weekly review | Validate |
| Executive learning brief | Not scheduled | Draft | Publish |
Limitation: The sequence is a planning model. It does not define clinical timeframes or guarantee that an intervention will improve outcomes. Stop, revise, or escalate the pilot when safety, equity, privacy, or workforce balancing signals warrant.
Days 1 to 30: define and observe
Name the sponsor, pathway owner, clinical authority, data steward, and patient partner. Write the boundary and exclusions. Observe a representative sample from result to closure. Verify how reference intervals, repeat tests, referral status, interpreter needs, and medication questions appear in the workflow. Establish baseline definitions and an exception queue before changing the route.
Days 31 to 60: test and review
Introduce one small change, such as a standardized interpreted-result message with named ownership and escalation, a reflex testing rule with safe exceptions, or a navigator-supported referral acknowledgment. Review exceptions weekly. Ask people and staff whether the route is understandable and usable. Do not expand the pilot while ownership, data quality, or safety review remains unstable.
Days 61 to 90: compare and decide
Compare the pilot with baseline using the predefined route, equity, safety, and workload measures. Examine missing data and unintended consequences. Decide to scale, revise, or stop. Publish a brief account of the problem, intervention, evidence boundary, result, limitations, remaining gaps, and the next review date.
Turn recognition into one route that people can trust.
Thyroid Awareness Month can create useful attention, but attention alone does not ensure appropriate testing, understandable choices, accepted referrals, affordable treatment, or closed-loop monitoring. The executive contribution is to make the path visible across organizational boundaries and to learn where it changes for different people.
Choose one bounded route this January. Put the people who use and operate it in the same review. Define an appropriate entry, a qualified interpretation, an understandable decision, an accepted next owner, a safe exception path, and a measurable close. Then show what improved, what did not, and what the organization will do next.
Start with the official observance and verified site pathways.
- American Thyroid Association: 2026 Thyroid Awareness Month toolkit
- The Healthcare Executive: 2026 Healthcare Observances Calendar
- The Healthcare Executive: Patient Experience & Access
- The Healthcare Executive: Operations, Quality & Safety
Source and usage note: The official toolkit supplies the 2026 observance identity and public campaign message. The operating models, figures, dashboard concepts, and 90-day plan in this brief are original executive applications informed by the peer-reviewed records below. No American Thyroid Association visual asset was reused, and this publication does not imply endorsement.
Safety note: This article supports leadership planning and education. It does not replace individualized medical advice, qualified clinical judgment, emergency procedures, professional standards, organizational policy, or applicable requirements. People with urgent symptoms should use the appropriate emergency or urgent-care route. Questions about testing, results, medications, pregnancy, surgery, or treatment should be directed to a qualified healthcare professional.
References
- Montagna C, Räsänen T, Zangelidis A. Epistemic injustice in healthcare: How doctor gender and speciality shape patient voice in women's thyroid care. Social Science & Medicine. Published online August 26, 2026. doi:10.1016/j.socscimed.2026.119743.
- Furuto Y, et al. Thyroid tests in kidney failure: diagnostic stewardship before levothyroxine therapy. Journal of Nephrology. Published online August 25, 2026. doi:10.1093/joneph/aajag230.
- Dao J, et al. Limited English Proficiency and Definitive Management for Graves' Disease. Journal of Surgical Research. Published online August 21, 2026. doi:10.1016/j.jss.2026.07.052.
- Leow MK. A geometric tensor-based computational framework for harmonizing thyroid function tests across laboratories with dissimilar reference intervals. Computer Methods and Programs in Biomedicine. Published online August 14, 2026. doi:10.1016/j.cmpb.2026.109608.
- Agarwal K, et al. Recent advances in the medical management of thyroid eye disease. Current Opinion in Endocrinology, Diabetes and Obesity. Published online August 13, 2026. doi:10.1097/MED.0000000000000972.
- Tang YL, et al. Financial Burden, Insurance Type, and Medication Adherence Among Community-Managed Patients with Hyperthyroidism. Patient Preference and Adherence. Published online August 11, 2026. doi:10.2147/PPA.S625835.
- Memeh K, et al. The role of insurance status in molecular testing for thyroid nodules with indeterminate cytology. Journal of the Endocrine Society. Published online August 5, 2026. doi:10.1210/jendso/bvag179.
- Ivens B, et al. Thyroid disorders, thyroid autoimmunity, and anxiety: a systematic review and meta-analysis. PeerJ. 2026;14:e21446. Published August 4, 2026. doi:10.7717/peerj.21446.
- Gan Y, et al. Trade-offs between disease label and treatment options: The case of low risk papillary thyroid cancer. Patient Education and Counseling. 2026;148. doi:10.1016/j.pec.2026.109532.
- Henricks C, et al. Long-term risk of hypothyroidism after thyroid abnormalities identified in pregnancy. American Journal of Obstetrics and Gynecology. Published online May 2026. doi:10.1016/j.ajog.2026.05.018.
- Larios F, et al. Factors and Outcomes of Inappropriate Thyroid Ultrasonography. JAMA Otolaryngology–Head & Neck Surgery. 2025;151(9):843-852. doi:10.1001/jamaoto.2025.2049.
- da Rocha BS, et al. Effects of timing and scheduling in levothyroxine adherence to hypothyroidism control: a meta-analysis of randomized clinical trials. Endocrine. 2025;89(1):52-61. doi:10.1007/s12020-025-04229-4.
- Zangouei Z, et al. The impact of self-care training using teach-back with telephone follow-up on adherence in patients with hypothyroidism. BMC Health Services Research. 2025;25:781. doi:10.1186/s12913-025-12962-9.
- Murthy S, et al. Reducing unnecessary free thyroid hormone testing by reinforcement of a reflexive algorithm. Clinical Biochemistry. 2025;137. doi:10.1016/j.clinbiochem.2025.110919.
- Singh P, Boelaert K. Controversies in thyroid disease management in pregnancy. Clinical Medicine. 2025;25(1). doi:10.1016/j.clinme.2025.100287.
- Ayhan YE, Bektay MY, Gogas Yavuz D, Sancar M. Evaluation of the clinical pharmacist's effect on achieving treatment goals in patients with hypothyroidism: a randomized controlled trial. BMC Endocrine Disorders. 2025;25:94. doi:10.1186/s12902-025-01914-3.
- Bengtsson E, et al. Observational study of diagnosis and management in adult primary hypothyroidism in southwest of Sweden. Scandinavian Journal of Primary Health Care. 2023;41(3):189-195. doi:10.1080/02813432.2023.2213748.
- Snyder M, et al. Weight stigma is associated with provider-patient relationship factors and adherence for individuals with hypothyroidism. Journal of Health Psychology. 2022;27(3):702-712. doi:10.1177/1359105320963548.
